Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | JDQ443 + TNO155 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JDQ443 | JDQ 443|JDQ-443 | KRAS G12C inhibitor 32 | JDQ443 inhibits KRAS G12C, which may lead to inhibition of downstream signaling and tumor progression (PMID: 35404998). | |
TNO155 | TNO-155|TNO 155 | SHP2 Inhibitor 19 | TNO155 is an inhibitor of PTPN11 (SHP2), which potentially blocks SHP2 signaling, thereby inhibiting activation of the MAPK pathway and subsequent tumor cell growth (NCI Drug Dictionary, Cancer Res (2022) 82 (12_Supplement): 1054). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04699188 | Phase Ib/II | JDQ443 JDQ443 + TNO155 JDQ443 + Tislelizumab + TNO155 JDQ443 + Tislelizumab | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 8 |